Overexpression of STK17B plays a crucial role in hepatocellular carcinoma and thus, inhibition of STK17B catalytic activity in cells implies clinical utility in the treatment of this malignancy (Lan et al., 2018). Here, STK17B is linked to hepatocellular carcinoma.